Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanO2 in mild respiratory distress
NCT06658535Phase 1Recruiting
- Sponsor
- NuvOx Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of perflenapent in respiratory distress syndrome (RDS) (3 cohorts), sponsored by NuvOx Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
perflenapent
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT06658535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658535.